Enovis Co. (NYSE:ENOV) Shares Acquired by Axa S.A.

Axa S.A. increased its position in Enovis Co. (NYSE:ENOV) by 26.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,798 shares of the company’s stock after buying an additional 4,326 shares during the period. Axa S.A.’s holdings in Enovis were worth $940,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Scout Investments Inc. acquired a new position in shares of Enovis in the first quarter valued at approximately $6,116,000. Price T Rowe Associates Inc. MD increased its position in Enovis by 88.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after purchasing an additional 179,276 shares during the last quarter. Tributary Capital Management LLC increased its position in Enovis by 15.6% during the first quarter. Tributary Capital Management LLC now owns 338,371 shares of the company’s stock worth $21,131,000 after purchasing an additional 45,745 shares during the last quarter. Quadrature Capital Ltd increased its position in Enovis by 175.5% during the fourth quarter. Quadrature Capital Ltd now owns 34,160 shares of the company’s stock worth $1,913,000 after purchasing an additional 21,760 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Enovis by 100.6% during the first quarter. Janus Henderson Group PLC now owns 378,020 shares of the company’s stock worth $23,606,000 after purchasing an additional 189,584 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ENOV. JPMorgan Chase & Co. dropped their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Evercore ISI dropped their price target on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, Needham & Company LLC dropped their price target on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.63.

Enovis Price Performance

ENOV opened at $41.47 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52-week low of $39.98 and a 52-week high of $65.03. The company has a 50 day moving average of $44.37 and a two-hundred day moving average of $49.10. The company has a market cap of $2.27 billion, a P/E ratio of -27.65 and a beta of 1.92.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.03. The business had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. On average, analysts expect that Enovis Co. will post 2.7 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.